A carregar...
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
BACKGROUND: Rivaroxaban is a selective inhibitor of coagulation factor Xa and its combination with aspirin showed better outcomes in the prevention of recurrent cardiovascular disease than aspirin alone. OBJECTIVE: This analysis aimed to economically compare the cost effectiveness of rivaroxaban (2....
Na minha lista:
| Publicado no: | Clin Drug Investig |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8149345/ https://ncbi.nlm.nih.gov/pubmed/33725323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-021-01023-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|